ARMP:NYE-Armata Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.475

Change

+0.08 (+3.13)%

Market Cap

USD 0.09B

Volume

1.40K

Analyst Target

USD 7.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

N/A

USD 585.29B
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD 3.60B
RCUS Arcus Biosciences Inc

N/A

USD 1.48B
NUVB Nuvation Bio Inc

N/A

USD 0.70B
ANRO Alto Neuroscience, Inc.

N/A

USD 0.35B
DNA Ginkgo Bioworks Holdings

N/A

USD 0.34B
ADCT ADC Therapeutics SA

N/A

USD 0.30B
CYBN Cybin Inc

N/A

USD 0.16B
ANVS Annovis Bio Inc

N/A

USD 0.10B
MAIA MAIA Biotechnology Inc.

N/A

USD 0.08B

ETFs Containing ARMP

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.61% 47% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.61% 47% F 8% B-
Trailing 12 Months  
Capital Gain -20.16% 55% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.16% 55% F 10% F
Trailing 5 Years  
Capital Gain -47.34% 60% D- 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.34% 60% D- 9% A-
Average Annual (5 Year Horizon)  
Capital Gain 7.18% N/A N/A 63% D
Dividend Return 7.18% N/A N/A 55% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 52.63% N/A N/A 17% F
Risk Adjusted Return 13.64% N/A N/A 35% F
Market Capitalization 0.09B 69% C- 25% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector